REGINfo: Lundbeck - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

OMXC 20 NEWS

> FLSmidth & Co.

> GN Store Nord

> Lundbeck

> Novo Nordisk B

> Royal UNIBREW

> Vestas Wind Systems

> William Demant Holding

FEEDS

My Google

Microsoft Live

My Yahoo

COMPANY SEARCH RESULT

$Lundbeck: Click to view the issuer\'s details$

Last update : 16/08/2018 >View issuer details

2019.03.26 | 14:16 | Annual General Meeting / AGM

puce Lundbeck held its Annual General Meeting on 26 March 2019 at the company’s registered office - HTML (w)

2019.03.08 | 09:00 | Permanent Information Releases / Appointments

puce Lundbeck appoints Keld Flintholm Jørgensen as EVP and Chief Business Officer - HTML (w)

2019.02.28 | 09:15 | Annual General Meeting / Preparatory Documents

puce Notice of Annual General Meeting - HTML (w)

2019.02.18 | 09:46 | Permanent Information Releases / Operations

puce Lundbeck increases its share capital by 5,631 shares (0.0028 % of outstanding shares) as a result of exercise of employee warrants - HTML (w)

2019.02.14 | 15:00 | Permanent Information Releases / General Company News

puce Lundbeck and Otsuka report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder - HTML (w)

2019.02.05 | 07:52 | Periodic information / Annual Financial Report

puce Annual Report 2018 for H.Lundbeck A/S - HTML (w)

2019.02.05 | 07:40 | Permanent Information Releases / Sales and Revenues

puce Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018 - HTML (w)

2019.02.05 | Periodic information / Annual Financial Report

puce Lundbeck : Annual Report 2018 - PDF (3Mb)

2019.01.22 | 06:32 | Permanent Information Releases / Appointments

puce Dr. Johan Luthman appointed EVP and Head of Research & Development in Lundbeck - HTML (w)

2018.12.04 | 09:38 | Permanent Information Releases / Appointments

puce Lundbeck announces retirement of Anders Gersel Pedersen, EVP and Head of Research and Development - HTML (w)

2018.11.30 | 09:17 | Permanent Information Releases / General Company News

puce Lundbeck and Otsuka report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD) - HTML (w)

2018.11.20 | 11:51 | Share History / Voting Rights and Number of Shares

puce Lundbeck increases its share capital by 6,574 shares (0.0033 % of outstanding shares) as a result of exercise of employee warrants - HTML (w)

2018.11.07 | 07:42 | Permanent Information Releases / Sales and Revenues

puce Lundbeck realized 12% growth in revenue (local currencies) and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised - HTML (w)

2018.11.07 | Periodic information / 3rd Quarter Information

puce Lundbeck : Financial report for the period 1 January to 30 September 2018 - PDF (1Mb)

2018.10.25 | 16:34 | Permanent Information Releases / General Company News

puce Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 / Doc nb : 90